Official websites use .gov

A .gov website belongs to an official government organization in the United States.

Secure .gov websites use HTTPS

A lock ( 🔒 ) or https:// means you've safely connected to the .gov website. Share sensitive information only on official, secure websites.

Need Help

Using transcriptomics and ex vivo organotypic models to discover mechanisms of APOL1-associated podocytopathies

Award Number: K01DK128304
ORGANIZATION: NATIONAL INSTITUTE OF DIABETES & DIGESTIVE & KIDNEY DISEASES
OPDIV: NIH
AWARD CLASS: DISCRETIONARY
AWARD ACTIVITY TYPE: TRAINING/TRAINEESHIP
PERIOD OF PERFORMANCE START DATE: 01/18/2023
PERIOD OF PERFORMANCE END DATE: 11/30/2027

Group Awards By:

View Award Description

Using transcriptomics and ex vivo organotypic models to discover mechanisms of APOL1-associated podocytopathies - ABSTRACT Chronic Kidney Disease (CKD) is common among African American (AA) patients. The excess risk for CKD in this population is partially explained by genetic variations in the APOL1 gene (named G1 and G2) that are unique to African ancestral populations. Understanding the molecular basis for the association between genetic variants and the risk for kidney disease is an important goal in biomedical science. The APOL1 gene is unique to humans and a few primates creating limitations to research approaches using conventionally available experimental models. This career development research proposal is designed to train a promising early stage investigator to address these issues by using organotypic kidney models derived from human inducible stem cells (iPSC) in conjunction with state-of-the-art bioinformatics to interrogate human patient data and explore therapeutics. The current proposal is designed to test the hypothesis that APOL1 kidney disease risk variants drive transcriptional differences that can be identified by the integration of glomerular transcriptomes from people with APOL1-associated kidney disease and ex vivo models, to gain insight into APOL1 function in health and disease. Key preliminary data developed by the applicant demonstrates that a variant-dependent APOL1 transcriptional signatures identified in human glomeruli are conserved in mouse models expressing APOL1 variants. The applicant will acquire new skills in two general areas: 1) expertise in the use of novel ex vivo culture models for mechanistic studies, and 2) computational and bioinformatics analysis of large datasets. These skills will be acquired through mentorship, didactics and a pragmatic research program divided into three specific aims: 1) Define APOL1 risk genotype-associated transcriptional phenotypes in podocytes derived from isogenic cell lines homozygous for the G0, G1 and G2 alleles that are anchored to human glomerular gene expression; 2) Anchor APOL1 variants-associated podocyte transcriptional phenotypes to NEPTUNE glomerular gene co-expression modules and clinical outcomes, and identity compounds that could modulate such phenotypes and associated subcellular processes, and 3) Test the chemical perturbagens’ ability to reverse the APOL1 risk genotype transcriptional phenotype and identify kidney disease mechanisms. Completion of this proposal will provide insights into APOL1 biology and function that could be translated to clinical technology by providing early diagnosis and prognosis tools, identification of therapeutic targets and patient derived renal models. Additionally this proposal aims to establish the Principal Investigator (PI) as an independent translational scientist in nephrology. The plan includes mentored training in patient oriented research, extensive wet-lab training in the production of organotypic models from iPSC lines as well as comprehensive coursework in bioinformatics.


Issue Date FY	Funding FY	Legal Entity Name	Legal Entity Address	Legal Entity City	Legal Entity State	Legal Entity Zip Code	Legal Entity COUNTY	Legal Entity COUNTRY	Assistance Listing	Award Code	Budget Year	Action Date	Action Type	Action Amount

Issue Date FY: 2026 ( Subtotal = $130,741 )
2026	2026	CASE WESTERN RESERVE UNIVERSITY	10900 EUCLID AVE	CLEVELAND	OH	44106	CUYAHOGA	USA	Diabetes, Digestive, and Kidney Diseases Extramural Research	000	4	12/10/2025	NON-COMPETING CONTINUATION	$130,741
														Subtotal = $130,741

Issue Date FY: 2025 ( Subtotal = $130,741 )
2025	2025	CASE WESTERN RESERVE UNIVERSITY	10900 EUCLID AVE	CLEVELAND	OH	44106	CUYAHOGA	USA	Diabetes, Digestive, and Kidney Diseases Extramural Research	000	3	2/19/2025	NON-COMPETING CONTINUATION	$130,741
														Subtotal = $130,741

Issue Date FY: 2024 ( Subtotal = $130,741 )
2024	2024	CASE WESTERN RESERVE UNIVERSITY	10900 EUCLID AVE	CLEVELAND	OH	44106	CUYAHOGA	USA	Diabetes, Digestive, and Kidney Diseases Extramural Research	000	2	11/8/2023	NON-COMPETING CONTINUATION	$130,741
														Subtotal = $130,741

Issue Date FY: 2023 ( Subtotal = $132,241 )
2023	2023	CASE WESTERN RESERVE UNIVERSITY	10900 EUCLID AVE	CLEVELAND	OH	44106	CUYAHOGA	USA	Diabetes, Digestive, and Kidney Diseases Extramural Research	000	1	1/18/2023	NEW	$132,241
														Subtotal = $132,241

Grand Total All Awards = $524,464

Top

All Categories

About

Search

Reports

Data Submission

Award Information

Using transcriptomics and ex vivo organotypic models to discover mechanisms of APOL1-associated podocytopathies

Award Number: K01DK128304

ORGANIZATION: NATIONAL INSTITUTE OF DIABETES & DIGESTIVE & KIDNEY DISEASES

OPDIV: NIH

AWARD CLASS: DISCRETIONARY

AWARD ACTIVITY TYPE: TRAINING/TRAINEESHIP

PERIOD OF PERFORMANCE START DATE: 01/18/2023

PERIOD OF PERFORMANCE END DATE: 11/30/2027

Federal Websites

Department of Health & Human Services

HHS Operating Divisions

HHS Staff Divisions

Download A Document Viewer